Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$403K Sell
1,146
-328
-22% -$117K 0.08% 82
2025
Q4
$483K Sell
1,474
-62
-4% -$19.7K 0.09% 68
2025
Q3
$434K Sell
1,536
-21,991
-93% -$6.38M 0.09% 68
2025
Q2
$6.57M Buy
23,527
+1,205
+5% +$341K 1.43% 25
2025
Q1
$6.95M Sell
22,322
-94
-0.4% -$27.8K 1.59% 21
2024
Q4
$5.84M Sell
22,416
-144
-0.6% -$42.7K 1.26% 30
2024
Q3
$7.27M Sell
22,560
-235
-1% -$76.9K 1.46% 26
2024
Q2
$7.12M Buy
22,795
+569
+3% +$167K 1.65% 21
2024
Q1
$6.32M Sell
22,226
-168
-0.8% -$49.2K 1.47% 24
2023
Q4
$6.45M Sell
22,394
-944
-4% -$257K 1.5% 26
2023
Q3
$6.27M Buy
23,338
+545
+2% +$136K 1.74% 15
2023
Q2
$5.06M Buy
22,793
+573
+3% +$133K 1.41% 28
2023
Q1
$5.37M Buy
22,220
+733
+3% +$180K 1.63% 24
2022
Q4
$5.64M Buy
21,487
+63
+0.3% +$16.9K 1.88% 15
2022
Q3
$4.83M Buy
21,424
+401
+2% +$97.2K 1.68% 17
2022
Q2
$5.12M Buy
21,023
+358
+2% +$87.7K 1.59% 19
2022
Q1
$5M Sell
20,665
-5,203
-20% -$1.2M 1.36% 27
2021
Q4
$5.82M Buy
25,868
+1,639
+7% +$346K 1.51% 26
2021
Q3
$5.15M Buy
24,229
+1,583
+7% +$364K 1.65% 21
2021
Q2
$5.52M Buy
22,646
+1,996
+10% +$491K 1.99% 15
2021
Q1
$5.14M Buy
20,650
+6,296
+44% +$1.5M 1.92% 13
2020
Q4
$3.3M Buy
+14,354
New +$3.31M 1.83% 22

Other funds holding AMGN

M. Kulyk & Associates's AMGN Position: Q1 2026 in Review

M. Kulyk & Associates reduced its Amgen (AMGN) stake by 22% in Q1 2026, selling an estimated $117K and leaving 1,146 shares worth $403K. The position accounts for 0.08% of the portfolio, ranked #82.

M. Kulyk & Associates first reported a position in AMGN in Q4 2020 and has held it in 22 quarters since. The position peaked at $7.27M in Q3 2024. 3,128 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

  • M. Kulyk & Associates held 1,146 shares of Amgen worth $403K as of Q1 2026.
  • M. Kulyk & Associates sold 328 Amgen shares in Q1 2026, an estimated $117K.
  • Amgen made up 0.08% of M. Kulyk & Associates's portfolio in Q1 2026, its #82 holding.
  • M. Kulyk & Associates first reported a position in Amgen in Q4 2020 and has held it in 22 quarters since.
  • M. Kulyk & Associates's Amgen position peaked at $7.27M in Q3 2024.
  • 3,128 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on M. Kulyk & Associates's 13F filing for Q1 2026, filed 6 May 2026.